On September 3, 2019 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), reported that management will be participating in the following two upcoming conferences this month (Press release, Infinity Pharmaceuticals, SEP 3, 2019, View Source [SID1234539227]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 2019 Healthcare Conference: Adelene Perkins, Infinity’s Chief Executive Officer, will present at Wells Fargo Securities14th Annual Healthcare Conference on Wednesday, September 4, 2019, at 1:50 p.m. ET at the Westin Copley Place in Boston, MA. A live webcast of the presentation will be available on the Investors/Media section of Infinity’s website at www.infi.com and will be available for 30 days following the event.

Morgan Stanley 17th Annual Global Healthcare Conference: Infinity’s management team will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11, 2019, at the Grand Hyatt New York, New York.